ICAR-19

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameICAR-19

Drug Alias Nameanti-CD19 CAR T-cell therapy (Immune Cell Therapy)ICAR-19

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-CellLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesImmune Cell Therapy Inc

China Registration ClassN/A

Develop Information

Active CompaniesImmune Cell Therapy Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellLeukemia

Inactive IndicationsN/A

Other Information

ATC CodeN/A